Bli medlem
Bli medlem

Du är här

2015-04-16

Medigene AG: Medigene to participate in three upcoming international conferences

Medigene AG / Medigene to participate in three upcoming international
conferences. Processed and transmitted by NASDAQ OMX Corporate Solutions. The
issuer is solely responsible for the content of this announcement.
Press Release

Martinsried/Munich, 16 April, 2015.
Medigene AG(MDG1, Frankfurt, Prime Standard) announces its participation in
three upcoming investment and scientific conferences:

* 8th Kempen&Co Healthcare&Life Sciences Conference

Date: 16 April 2015

Location: New York, USA

* AACR Annual Meeting 2015

Date: 18 - 22 April 2015

Location: Philadelphia, USA
Medigene's academic partner, the Oslo University Hospital (Prof.
Gunnar Kvalheim, Head of Department of Cellular Therapy) will present
clinical data of its DC vaccine program.[1]

Presentation Time: Monday, 20 April 2015, 1:00 pm - 5:00 pm local
time

* 3rd CIMT Endeavour Workshop

Date: 12 May 2015

Location: Mainz, Germany
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG
will give a presentation titled "The long and short history of Trianta
Immunotherapies: From virtual academic spin-out to subsidiary of Medigene AG"

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. Medigene concentrates on
the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed
to partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visitwww.medigene.com.

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®EndoTAG®and Veregen®are registered
trademarks of Medigene AG. These trademarks may be owned or licensed in
select locations only.

Contact Medigene

Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please
visit:http://www.medigene.de/unsubscribe
---------------------------------------[1]The Oslo University Hospital has an agreement with Medigene for use of
Medigene`s new generation DC vaccines for their ongoing academic clinical
studies.

Press release as PDF
http://hugin.info/132073/R/1911462/682022.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#1911462

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.